Hold off on skincare until after you’ve applied the patch. Avoid using serums and heavy moisturizers under the pimple patch, ...

Isotretinoin is a synthetic type of vitamin analogue used as a first-line treatment for severe nodular acne. Talk to your provider about the risks and side effects of using it, especially if you want ...

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne. Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...

Of the 19,907 patients, 35% received a subsequent prescription acne treatment, with 22.5% receiving an oral medication; 8.2% were treated with a second course of isotretinoin.

If you’ve been struggling with acne scars and haven’t found a treatment that works, there’s a promising frontier in skin repair: stem cell therapy.Severe acne can lead to long-lasting acne ...

Potential Positives. Denifanstat met all primary and secondary endpoints in a Phase 3 clinical trial, demonstrating its efficacy for the treatment of moderate to severe acne vulgaris.

Back acne and body acne are common problems. Around 85% of people between the ages of 12 and 24 will have acne in some form, and many people will continue to experience acne into their 30s and 40s.

Sanofi has added to its vaccine pipeline with an agreement to acquire Austria's Origimm Biotechnology and its vaccine-based immunotherapy for people with acne. The French group said that ORI-001 ...

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...

Hong Kong biotech Ascletis is planning to file a new oral treatment for acne for approval in China soon, on the back of new phase 3 data that suggests it could be a big step forward in treatment ...

Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor ...